UNSPSC 51112902: Temozolomide

This classification denotes a triazene compound and gonadotropin releasing hormone inhibitor with the molecular formula C6H6N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YF1K15M17Y, chemically known as 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide but more generally known as temozolomide, which bears US NIH Compound Identifier 5394. European Medicines Agency schedules Temozolomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10889MIG.

UNSPSC 51112902 Temozolomide is a Commodity code covering the procurement of this chemotherapy drug by state and local health systems, corrections departments, and other public health agencies. Temozolomide is an oral alkylating agent used primarily to treat glioblastoma and other brain tumors; state and local buyers source it through pharmaceutical vendors, group purchasing organizations (GPOs), and state Medicaid formularies. The code reflects routine pharmaceutical procurement rather than one-time or project-based acquisitions — issuing bodies include state Medicaid agencies, county health departments, state prison systems, and public hospital systems that maintain standing inventory and renewal contracts for oncology medications.

The source material does not contain a block of recent state and local solicitation activity for this Commodity code. Without posted RFPs, RFQs, ITBs, or other contract notices naming Temozolomide, geographic concentration and representative recent opportunities cannot be established from this record. Buyers of this drug typically operate through established group purchasing agreements, standing state Medicaid contracts, and national pharmaceutical distribution channels rather than through individual competitive solicitations, which may explain the absence of recent posted notices under this specific UNSPSC code.